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OBSERVED DIFFERENCES BETWEEN DAILY DIARY AND
WEEKLY REPORT OF CYSTIC FIBROSIS SYMPTOMS
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OBJECTIVE: Recent reviews of human memory processes in
cognitive psychology suggest that shorter recall periods in
patient-reported outcome (PRO) measures capture daily expe-
rience more accurately. Few empirical studies quantify patient
symptom reporting by length of the recall period. This study
compares 7-day recall of symptoms during the past week with
24-hour recall in a daily diary to determine whether the recall
period yields signiﬁcant differences in measures of patient
reported symptom occurrence and severity. METHODS: The
Cystic Fibrosis Respiratory Diary (CFRD) is a recently devel-
oped PRO including 13 symptoms (e.g. cough, tiredness, frus-
tration) in which patients record the occurrence and severity of
symptoms for six consecutive days using a 24-hour recall
period and on the seventh day using a 7-day recall period.
Cystic ﬁbrosis patients age 2 and older (parents for children age
11 or younger), completed two diaries while clinically stable
and one during a pulmonary exacerbation requiring medical
attention beyond their usual care. This analysis identiﬁes how
often patients’ 7-day recall of symptom occurrence (a
symptom-speciﬁc item with yes/no response) matches their six
day pattern of 24-hour recall (none/any), and compares 7-day
recall of symptom severity (4-category response scale, 0 to 3,
most severe is 3) to averaged daily 24-hour recall using a paired
t-test. RESULTS: A total of 1235 week-long symptom obser-
vations analyzed from 95 out of 145 diaries completed for all
seven days, represent 52 out of 56 participants. A total of
1,080/1235 (87%) of the 7-day recalls of symptom occurrence
matched the 6 day none/any pattern of daily 24-hour recall.
7-day recall of symptom severity (Mean, 0.42; SD, 0.77) was
greater than averaged daily 24-hour recall (Mean, 0.34; SD,
0.62) (p < 0.001). CONCLUSION: A 7-day recall period does
not produce the same results as daily 24-hour recall in a week-
long symptom diary.
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OBJECTIVE: The objective of this study was to assess reductions
in pain frequency and intensity in cervical dystonia patients
treated with botulinium toxin (BoNT-A). METHODS: A total of
170 patients were randomized to receive (BoNT-A) or placebo as
part of a 10-week, double-blind study. Patients assessed their
pain frequency on a scale from 0 (never) to 4 (constant) and their
pain intensity on a scale from 0 (none) to 4 (very severe). Pain
frequency and intensity were measured at follow-up visits at
weeks 2, 4, 6, 8, and 10. RESULTS: The mean baseline pain
frequency scores were 1.79 for the BoNT-A group and 1.91 for
the placebo group. The reduction in mean change of pain fre-
quency ranged from -0.19 to -0.37 in the BoNT-A group and
from -0.01 to -0.20 in the placebo group. A greater reduction in
the mean change in pain frequency was seen at all timepoints in
the botulinium toxin group; the difference was statistically sig-
niﬁcant at week 6 (-0.31 vs -0.01; P = 0.018). The mean baseline
pain intensity scores were 1.78 in the BoNT-A group and 1.80 in
the placebo group. The reduction in the mean change of pain
intensity ranged from -0.20 to -0.47 in the BoNT-A group, while
the placebo group had an increase in pain intensity at week 6, no
change from baseline at week 10, and reductions ranging from
-0.06 to -0.18 at other timepoints. The mean change in pain
intensity showed a greater reduction at all timepoints in the
BoNT-A group compared to placebo, with the difference being
statistically signiﬁcant at week 2 (-0.39 vs -0.07; P = 0.026) and
week 6 (-0.36 vs 0.06; P  0.001). Adverse events rates were
nearly equivalent between groups (59.1% BoNT-A vs. 58.5%
placebo group). CONCLUSION: Treatment with BoNT-A
lowered frequency and intensity of patient-assessed pain as com-
pared to placebo.
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EVALUATION OF INTERVIEWERTRAINING FOR AN
INTERVIEWER ADMINISTERED PATIENT-REPORTED
OUTCOME IN A GLOBAL CLINICALTRIAL
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OBJECTIVE: Patient reported outcomes (PROs) play an increas-
ingly important role in pharmaceutical clinical trials. The Food
and Drug Administration (FDA) recognizes that interviewer
training affects PRO study results. Further, the FDA asserts that
implementation of standardized interviewer training can opti-
mize study quality by minimizing inconsistencies in trial conduct.
Presently, there is no standard PRO interviewer training method,
and many registration trials neglect this important aspect of
ensuring quality data. To test the effectiveness of such training,
United BioSource Corporation (UBC) analyzed outcomes of PRO
interviewer training in a global clinical trial. METHODS: United
BioSource Corporation worked in conjunction with a pharma-
ceutical sponsor to develop a training program for an interviewer
administered PRO designed to assess symptom severity and
resultant distress to patients. Custom training on instrument
content, format and administration guidelines was provided to
519 potential interviewers live (70%) at 4 separate investigator
meetings (Nashville, Geneva, Kuala Lumpur, Buenos Aires), or
via the internet for those unable to attend an IM (30%). Follow-
ing training, interviewer knowledge was independently assessed
using an exam speciﬁcally created for that purpose. RESULTS: A
total of 519 interviewers completed the training. Seventy-four
percent of interviewers had no previous instrument speciﬁc expe-
rience. A total of 506 (97.5%) demonstrated scale knowledge
mastery (80% or greater). As shown by one-way ANOVAs,
performance was not affected by nationality, clinical experience,
clinical trials experience, or prior experience with the instrument
(all F ratios <1). CONCLUSION: We report the global delivery
of a comprehensive PRO interviewer training package consistent
with FDA goals. The study suggests that comprehensive PRO
interviewer training is feasible in multinational trials, is effective
in live or remote delivery platforms, and results in high levels of
demonstrable scale knowledge across a wide range of clinical and
research experience levels.
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OBJECTIVE: The objective of this analysis was to evaluate func-
tional disability in patients with cervical dystonia. METHODS:
The study consisted of a 10-week, non-randomized, open-label
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period followed by a 10-week, randomized, double-blind,
placebo-controlled period. A total of 170 patients were random-
ized to receive a physician-determined dose of botulinium toxin
type A (BoNT-A) or placebo. Functional disability was measured
by patients and physicians using a scale from 0 (no functional
disability) to 4 (very severe disability). Functional disability was
measured at study visits at weeks 2, 4, 6, 8, and 10 of the
randomized, double-blind period of the study. RESULTS: The
baseline mean physician-assessed functional disability scores
were 1.87 for botulinium toxin and 1.88 for placebo. The mean
change in physician-assessed functional disability showed a
greater reduction in the BoNT-A group compared with the
placebo group at all timepoints, with the difference being signiﬁ-
cant at weeks 4, 6, and 8 (P  0.029). A higher proportion of
patients had a decrease of one grade or more in physician-
assessed functional disability in the BoNT-A group at all time
periods. The baseline mean patient-assessed functional disability
scores were 1.95 in the BoNT-A group and 1.78 in the placebo
group. A greater reduction in the mean change of patient-
assessed functional disability was seen with BoNT-A compared
with placebo at all timepoints. The patient-assessed functional
disability between the two groups was signiﬁcantly different at
weeks 2, 6, 8, and 10 (P  0.008). A one grade or greater
reduction in patient-assessed functional disability was experi-
enced by a higher proportion of botulinium toxin patients at all
timepoints compared with placebo. Rates of adverse events were
nearly equivalent between groups (59.1% BoNT-A vs. 58.5%
placebo group). CONCLUSION: Treatment with BoNT-A
showed signiﬁcant and sustained improvements in functional
disability when assessed by both the physician and the patient.
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OBJECTIVE: Most Multiple Sclerosis (MS) clinical trials focus
on relapses and MRI measures of disease activity. Disease
outcome measures in clinical trials and practice focus on physical
outcomes and, in particular, the ambulation oriented Expanded
Disability Severity Scale (EDSS). This study evaluated the rela-
tionships between various physical and patient reported out-
comes (PROs) in MS patients. METHODS: Charts were
abstracted for 98 MS patients in a single MS center that captured
both physician-evaluated outcomes and PROs. This study
reports the last available evaluation. Spearman rank correlations
and a recursive partitioning algorithm were used to evaluate
relationships between ﬁve physical (box/blocks, 9-hole peg,
timed walk, Tinetti balance, and EDSS) and 3 PRO (modiﬁed
fatigue impact scale, Beck depression inventory, and Espworth
sleepiness scale) measures in addition to standard demographic
and disease characterizing variables. RESULTS: The rank corre-
lation between the box/blocks and nine-hole peg tests (standard
tests for ﬁne motor control) was 0.9 (p < 0.001) while the rank
correlation between box/blocks and timed walk was 0.71
(p < 0.001). Moderate correlations were observed for the PROs:
fatigue and depression was 0.57 (p < 0.001); fatigue and sleepi-
ness was 0.52 (p < 0.001); and depression and sleepiness was
0.39 (p < 0.001). No signiﬁcant correlations were observed
between either depression or sleepiness and any physical
outcome measure. Fatigue was correlated with 9-hole peg (0.41,
p = 0.023), timed walk (0.44, p = 0.014), and EDSS (0.34,
p = 0.013). The recursive partitioning algorithm found the stron-
gest physical outcome associated with fatigue to be EDSS and the
best split was at EDSS <= (“minimal” versus “mild” disability).
CONCLUSION: Moderate correlations were found within the
physical outcome measures and within PROs; but the relation-
ship between physical outcomes and PROs was weak. Because
most clinical trials and evaluating neurologists focus on physical
measures in MS, it is likely that much of the disease impact is
being missed.
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PHYSICIAN AND PATIENT REPORTED OUTCOMES REVEAL
RAPID ONSET OF IMPROVEMENT AND OVERALL
CONVENIENCE,TOLERABILITY AND EASE-OF-USEWITH
RASAGILINE IN PARKINSON’S DISEASE (PD) IN LEGATO
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OBJECTIVE: To evaluate investigator and patient-reported sat-
isfaction and ease-of-use of Azilect(r) (rasagiline tablets) in com-
munity neurological practices. Rasagiline is a potent, once daily,
novel, irreversible MAO-B inhibitor approved for PD as initial
monotherapy or adjunct therapy. Pivotal trials showed improve-
ment in the Uniﬁed Parkinson’s Disease Rating Scale for mono-
therapy and reduced OFF time for adjunct therapy. Other
measures of patient- and investigator-reported outcomes may
be important such as ease-of-use and patient satisfaction.
METHODS: LEGATO is an open-label study of once-daily rasa-
giline 0.5 mg and 1 mg in PD patients at 38 community-based
centers. Baseline treatment determined patients’ stratiﬁcation to
adjunct or monotherapy. Evaluations were at weeks 1, 2, 4, and
12. Endpoints included: patient and investigator reported Clini-
cal Global Improvement(CGI) score; investigator-and patient-
reported change from baseline in Schwab & England Activities
of Daily (ADL) score; and investigator-and patient-reported
satisfaction/ease-of-use ratings. RESULTS: A total of 272
patients were enrolled: 123 monotherapy patients and 149
adjunct patients with 245 completers. At all visits, investigator
reported CGI was signiﬁcantly improved for both mono and
adjunct therapy (p < 0.001). At all visits, patient reported CGI
was also signiﬁcantly improved for both mono and adjunct
therapy (p < 0.001). Patient-reported CGI was similar to Inves-
tigators’, although maximal improvement occurred later for
patients. Median satisfaction/ease-of-use scores were 9 for mono-
therapy (range 6 to 30 with 6 being best) and 10 for adjunct
therapy (range of 8 to 40 with 8 being best) for both patients
and investigators. Investigators noted statistically signiﬁcant
improvement in ADL of 3 points at the end of 12 weeks, whereas
patients did not note changes from baseline. CONCLUSION:
Both investigators and patients noted signiﬁcant effectiveness
beginning at week one as measured by CGI, found rasagiline
convenient and easy to use, and were satisﬁed with the dosing
frequency and tolerability of once-daily rasagiline.
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THE DEVELOPMENT OF A PATIENT SATISFACTION
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OBJECTIVE: The purpose of this study was to develop an instru-
ment to assess treatment satisfaction for patients with insomnia.
METHODS: Speciﬁc patient satisfaction items were identiﬁed
from the existing literature by an expert panel of physicians,
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